Liraglutide with mealtime insulin versus glargine with mealtime insulin in overweight type 2 diabetes
Compares liraglutide and glargine, each with mealtime insulin, in overweight adults with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)
Key facts
- Where
- Xiamen, ChinaSee the site
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT03087032, who can take part
Where in China
- The first afilliated hospital of Xiamen universityXiamen, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The First Affiliated Hospital of Xiamen University
- Trial code
- NCT03087032
- Record updated
- 13 January 2025
- Original description
The present 24-week, prospective, open-label, randomized, multicenter, parallel group trial is carried to investigate and evaluate the efficacy and safety of Liraglutide in combination with prandial insulin therapy vs insulin glargine in combination with prandial insulin therapy in overweight / obese patients with uncontrolled type 2 diabetes.Read full original descriptionShow less
Efficacy and Safety of Liraglutide-bolus (Liraglutide Plus Prandial Insulin) Versus Glargine-bolus Therapy in Overweight / Obese Patients With Uncontrolled Type 2 Diabetes (LiraGooD)--A Multicenter Randomized Controlled Study
The present 24-week, prospective, open-label, randomized, multicenter, parallel group trial is carried to investigate and evaluate the efficacy and safety of Liraglutide in combination with prandial insulin therapy vs insulin glargine in combination with prandial insulin therapy in overweight / obese patients with uncontrolled type 2 diabetes.
Inclusion: Age: 18 - 75 years old; BMI must be greater than 24 and less than 45 kg/m2; Patients with type 2 diabetes who met the World Health Organization (who) diagnostic criteria (1999); Newly diagnosed type 2 diabetic patients with HbA1c ≥ 9.0%；or patients with uncontrolled type 2 diabetes (HbA1c ≥ 7.5% ) who have received at least two types of oral hypoglycemic drugs (the dose of each drug needs to reach the second largest dose or more), or only insulin (excluding basal-bolus insulin therapy), or insulin with oral hypoglycemic drugs; Signed informed consent.
Exclusion: History of pancreatic disease,; History of medullary thyroid carcinoma; Evidence in the last 6 months of significant heart disease or stroke, including myocardial infarction, unstable angina, coronary bypass and/or percutaneous transluminal coronary angioplasty, congestive heart failure (New York Heart Association Functional Classification III-IV), or severe ischemic heart disease; Creatinine clearance ≤ 30 mL/min/1.73m2,; Lipase level > 3 times above normal,; Preparation for pregnancy or having been in pregnancy; Researchers believe that there are any factors that affect assessing subjects' participation in trial; Patients unable to cooperate in clinical trials.